We provide an update of the trajectory of the migration of next-generation sequencing (NGS) from the research space toward clinical application and clinical impact in this GEN report as part of our continuing coverage of the evolution of the NGS industry landscape.
Highlights of this report:
- There are defined research offerings from several vendors for NGS front-end sample processing and preparation.
- Many of these kit-formatted products are available and are designed for research use (RUO).
- There is a defined clinical translation of NGS that is taking place, and one of the key drivers of this translation toward the clinic is the approval of the Illumina MiSeqDx platform by the FDA.
- Indeed today there are a number of LDTs deploying NGS with specific gene panels—primarily focusing on oncology—but expanding out into other disease classes also.
- The development of ecosystems of researchers developing NGS-based applications will propel this translation of NGS from research to clinic.